SRR10900575
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.929 |
| 2 | SRR934963 | — | — | 0.913 |
| 3 | TCGA-70-6722-01A-11R-1820-07 | — | cohortSQ1 | 0.910 |
| 4 | BS_NR3P3GN2 | high-grade glioma | — | 0.908 |
| 5 | SRR8942948 | — | — | 0.906 |
| 6 | BS_1AYRM596 | Med | Medulloblastoma | 0.901 |
| 7 | SRR934881 | — | — | 0.900 |
| 8 | TCGA-FD-A6TK-01A-42R-A33J-07 | — | — | 0.896 |
| 9 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.896 |
| 10 | R409 | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |